Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06602024 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
A Phase 3 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 40,817
- Enrollment target
NCT06602024: Completed Phase 3 study, sponsored by ModernaTX.
NCT06602024 is a Phase 3 study that has completed, run by ModernaTX. The registered enrollment target is 40,817 participants, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (5208% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06602024, a Phase 3 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40,817 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
Interventions
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Fluarix®
- BIOLOGICAL Influsplit® Tetra
- BIOLOGICAL Fluarix Tetra
- BIOLOGICAL Alpharix® Tetra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,817 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2025-08-21 |
| Phase | Phase 3 |
What the finished NCT06602024 record still lists
NCT06602024 is an interventional study that assigns participants to a tested intervention. Its 40,817 participants enrollment target places it among the larger protocols in the corpus, above the 769-participant average among 15,282 other Phase 3 trials with a reported enrollment target (5208% higher).
The record links to 0 conditions, and to 5 interventions - of which mRNA-1010 is the first listed.
NCT06602024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06602024 about?
NCT06602024 is a clinical study titled "A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age". The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness...
What is the current status of trial NCT06602024?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40,817 participants. The study started on 2024-09-16. Estimated completion is 2025-08-21.
What interventions are being tested in trial NCT06602024?
The interventions under investigation include: mRNA-1010 (BIOLOGICAL), Fluarix® (BIOLOGICAL), Influsplit® Tetra (BIOLOGICAL), Fluarix Tetra (BIOLOGICAL), Alpharix® Tetra (BIOLOGICAL).
Who is sponsoring clinical trial NCT06602024?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06602024's enrollment target sits among peer trials
40,817 3rd of 2000 higher than 1,998 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI